Prospective, randomized, placebo-controlled, multicenter, double-blind, parallel-group, registration field trial evaluating izenivetmab, a caninized anti-nerve growth factor monoclonal antibody, administered quarterly to dogs with naturally occurring osteoarthritis
Hilde Moyaert, Gina M. Michels, Helena Berlamont, Karen Akkermans, Bernard D. Hummel, Jezaniah Kira S. Tena, Maria J Corral, Ignacio Gisbert, Dawn M. Cleaver, Michael R Stegemann Veterinary and Animal Science
· Elsevier
· 2026-12-01
· DOI: 10.1016/j.vas.2026.100872
The publisher did not provide an abstract — full text is available via the link below.
Hilde Moyaert, Gina M. Michels, Helena Berlamont, Karen Akkermans, Bernard D. Hummel, Jezaniah Kira S. Tena et al. Prospective, randomized, placebo-controlled, multicenter, double-blind, parallel-group, registration field trial evaluating izenivetmab, a caninized anti-nerve growth factor monoclonal antibody, administered quarterly to dogs with naturally occurring osteoarthritis. // Veterinary and Animal Science. – 2026. – DOI: 10.1016/j.vas.2026.100872. – URL: https://doi.org/10.1016/j.vas.2026.100872
Hilde Moyaert, Gina M. Michels, Helena Berlamont, Karen Akkermans, Bernard D. Hummel, Jezaniah Kira S. Tena, Maria J Corral, Ignacio Gisbert, Dawn M. Cleaver, & Michael R Stegemann (2026). Prospective, randomized, placebo-controlled, multicenter, double-blind, parallel-group, registration field trial evaluating izenivetmab, a caninized anti-nerve growth factor monoclonal antibody, administered quarterly to dogs with naturally occurring osteoarthritis. Veterinary and Animal Science. https://doi.org/10.1016/j.vas.2026.100872
Hilde Moyaert, et al. “Prospective, randomized, placebo-controlled, multicenter, double-blind, parallel-group, registration field trial evaluating izenivetmab, a caninized anti-nerve growth factor monoclonal antibody, administered quarterly to dogs with naturally occurring osteoarthritis.” Veterinary and Animal Science, 2026. doi:10.1016/j.vas.2026.100872.
@article{Moyaert2026,
title = {Prospective, randomized, placebo-controlled, multicenter, double-blind, parallel-group, registration field trial evaluating izenivetmab, a caninized anti-nerve growth factor monoclonal antibody, administered quarterly to dogs with naturally occurring osteoarthritis},
author = {Moyaert, Hilde and Michels, Gina M. and Berlamont, Helena and Akkermans, Karen and Hummel, Bernard D. and Tena, Jezaniah Kira S. and Corral, Maria J and Gisbert, Ignacio and Cleaver, Dawn M. and Stegemann, Michael R},
journal = {Veterinary and Animal Science},
year = {2026},
doi = {10.1016/j.vas.2026.100872},
url = {https://doi.org/10.1016/j.vas.2026.100872}
}